Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94:2986–3005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35277864.

Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9:e13952. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36855648.

Bell LCK, Meydan C, Kim J, Foox J, Butler D, Mason CE, et al. Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19. iScience. 2021;24:101896. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33319166.

Tripathy AS, Vishwakarma S, Trimbake D, Gurav YK, Potdar VA, Mokashi ND, et al. Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection. Arch Virol. 2021;166:3301–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34554303.

Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 34:327–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32171193.

Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol. 2020;11:1518. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32655582.

McCarty MF, Iloki Assanga SB, Lewis Luján L, O’Keefe JH, DiNicolantonio JJ. Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. Nutrients. 2020;13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33375692.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2:e393–400. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32835245.

Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep. 2020;10:21775. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33311551.

Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, Ziya Gencer M, Ammari A, Sadeghi A, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020;89:107088. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33129099.

Effendi WI, Nagano T. The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases. Int J Mol Sci. 2021;22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34638790.

Swanson K V, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31036962.

Albanese V, Missiroli S, Perrone M, Fabbri M, Boncompagni C, Pacifico S, et al. Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer. J Med Chem. 2023;66:5223–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36972104.

De Ventura T, Perrone M, Missiroli S, Pinton P, Marchetti P, Strazzabosco G, et al. Synthesis and NLRP3-Inflammasome Inhibitory Activity of the Naturally Occurring Velutone F and of Its Non-Natural Regioisomeric Chalconoids. Int J Mol Sci. 2022;23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36012241.

Ka S-M, Kuoping Chao L, Lin J-C, Chen S-T, Li W-T, Lin C-N, et al. A low toxicity synthetic cinnamaldehyde derivative ameliorates renal inflammation in mice by inhibiting NLRP3 inflammasome and its related signaling pathways. Free Radic Biol Med. 2016;91:10–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26675345.

Liu P, Wang J, Wen W, Pan T, Chen H, Fu Y, et al. Cinnamaldehyde suppresses NLRP3 derived IL-1β via activating succinate/HIF-1 in rheumatoid arthritis rats. Int Immunopharmacol. 2020;84:106570. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32413739.

Zareie A, Soleimani D, Askari G, Jamialahmadi T, Guest PC, Bagherniya M, et al. Cinnamon: A Promising Natural Product Against COVID-19. Adv Exp Med Biol. 2021;1327:191–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34279839.

Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920304837.

Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, et al. Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients. Front Immunol. 12:648004. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33767713.

Xu F, Wang F, Wen T, Sang W, Wang D, Zeng N. Inhibition of NLRP3 inflammasome: a new protective mechanism of cinnamaldehyde in endotoxin poisoning of mice. Immunopharmacol Immunotoxicol. 2017;39:296–304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28762847.

Bessler H, Mendel C, Straussberg R, Gurary N, Aloni D, Sirota L. Effects of dexamethasone on IL-1beta, IL-6, and TNF-alpha production by mononuclear cells of newborns and adults. Biol Neonate. 1999;75:225–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10026370.

Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8:8618. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29872077.

Wilson JG, Simpson LJ, Ferreira A-M, Rustagi A, Roque J, Asuni A, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI insight. 2020;5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32706339.

Lu Q, Zhu Z, Tan C, Zhou H, Hu Y, Shen G, et al. Changes of serum IL-10, IL-1β, IL-6, MCP-1, TNF-α, IP-10 and IL-4 in COVID-19 patients. Int J Clin Pract. 2021;75:e14462. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34107113.

Gulec Peker EG, Kaltalioglu K. Cinnamaldehyde and eugenol protect against LPS-stimulated oxidative stress and inflammation in Raw 264.7 cells. J Food Biochem. 2021;45:e13980. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34676584.

Mohd Zaid NA, Sekar M, Bonam SR, Gan SH, Lum PT, Begum MY, et al. Promising Natural Products in New Drug Design, Development, and Therapy for Skin Disorders: An Overview of Scientific Evidence and Understanding Their Mechanism of Action. Drug Des Devel Ther. 2022;16:23–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35027818.

Ferreira AS, Macedo C, Silva AM, Delerue-Matos C, Costa P, Rodrigues F. Natural Products for the Prevention and Treatment of Oral Mucositis-A Review. Int J Mol Sci. 2022;23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35457202.

Alesci A, Lauriano ER, Fumia A, Irrera N, Mastrantonio E, Vaccaro M, et al. Relationship between Immune Cells, Depression, Stress, and Psoriasis: Could the Use of Natural Products Be Helpful? Molecules. 2022;27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35335319.

Feng Z, Zheng W, Li X, Lin J, Xie C, Li H, et al. Cryptotanshinone protects against IL-1β-induced inflammation in human osteoarthritis chondrocytes and ameliorates the progression of osteoarthritis in mice. Int Immunopharmacol. 2017;50:161–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28666239.

Castejón ML, Rosillo MÁ, Montoya T, González-Benjumea A, Fernández-Bolaños JG, Alarcón-de-la-Lastra C. Oleuropein down-regulated IL-1β-induced inflammation and oxidative stress in human synovial fibroblast cell line SW982. Food Funct. 2017;8:1890–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28426090.

Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021;10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33682678.

Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34480127.

Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3:e690–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34396156.

Amaral-Machado L, Oliveira WN, Rodrigues VM, Albuquerque NA, Alencar ÉN, Egito EST. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients? Biomed Pharmacother. 2021;134:111143. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33360048.

Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Curr Res Pharmacol drug Discov. 2022;3:100086. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35136858.

Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36639608.

Perumal R, Shunmugam L, Naidoo K, Abdool Karim SS, Wilkins D, Garzino-Demo A, et al. Long COVID: a review and proposed visualization of the complexity of long COVID. Front Immunol. 2023;14:1117464. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37153597.

Campo G, Contoli M, Fogagnolo A, Vieceli Dalla Sega F, Zucchetti O, Ronzoni L, et al. Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets. 2021;32:560–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33270471.

Spadaro S, Fogagnolo A, Campo G, Zucchetti O, Verri M, Ottaviani I, et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care. 2021;25:74.

Article  PubMed  PubMed Central  Google Scholar 

Bortolotti D, Gentili V, Rotola A, Cultrera R, Marci R, Di Luca D, et al. HHV-6A infection of endometrial epithelial cells affects immune profile and trophoblast invasion. Am J Reprod Immunol. 2019;82:e13174. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31338899.

Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Strazzabosco G, et al. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms. 1820;2021:9.

Google Scholar